]> 2026-04-12T02:22:45-07:00 Optune 0 en Most common adverse reaction is skin irritation at the device contact points; no increase in systemic adverse events 2025-01-18T08:24:49Z 2460693.8505671 Optune 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Optune, now including Optune Gio\u00ae as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients."] Optune# ERRa3f62c6665776505f0db7c26c19aebf1